Mavyret approved as 8-week treatment for hep C, compensated cirrhosis

Health Problems

(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through 6 and compensated cirrhosis, the U.S. Food and Drug Administration announced last week. Mavyret is the first eight-week treatment approved for any treatment-naive HCV patients, regardless of cirrhosis status or […]

Continue reading »

A third of bacterial infections in patients with cirrhosis across the world are multi-drug resistant

Health Problems

A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant (MDR) bacteria of 34% and significant regional differences in the risk of developing a multi-drug-resistant infection. Research teams from 46 centres across the world collaborated in this international study, which was promoted by the International […]

Continue reading »